Результаты поиска

Ось Гут-Брэйна в нейродегенерации: механистические связи между дисбиозом и нейроатологией.

& ЦЕЛЬ: Ось кишечника по сути представляет собой two- система связи, которая физически соединяет мозг с кишечным трактом. Связь поддерживается через ряд путей, включая нейронные, эндокринные и иммунные пути. Гут дисбиоз, который объясняется как дисбаланс в микробном сообществе, связан с причинно-следственной связью различных нейродегенеративных расстройств, таких, как болезнь Альцгеймера, болезнь Паркинсона и множественный склероз. Однако патологические механизмы в мозге известны лишь частично. В настоящем обзоре описывается процесс кишечного дисбиоза и нейродегенерации с подробным описанием ф

Progress in high-throughput screening for drug and material discovery in orthopedic diseases: a literature review.

Orthopedic diseases are referred to as a series of conditions affecting the normal structure and function of the skeletal system. With a wide variety of types and a year-by-year increasing incidence, they have a severe impact on patients' quality of life. Traditional research has made relatively significant progress in understanding the pathogenesis and treating orthopedic diseases, however, it remains constrained by limitations such as low-throughput experimentation, and difficulty in mimicking the complex bone microenvironment. In recent years, high-throughput screening (HTS) technology has

Revolutionising health care: Exploring the latest advances in medical sciences.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Cellular therapies for rheumatic disease.

PURPOSE OF REVIEW: Cellular therapies, particularly chimeric antigen receptor (CAR)-modified lymphocytes, have progressed from experimental oncology into serious consideration for selected autoimmune rheumatic diseases. Autologous and emerging allogeneic CAR-T platforms now offer the possibility of deep, drug-free remission in systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), systemic sclerosis (SSc), and related conditions for which conventional therapies remain inadequate. This timely article reviews the rationale, current clinical experience, safety profile, and

Поощрение использования продольных электронных медицинских записей: обучение по изучению реальных мировых данных о последствиях хронических заболеваний.

Для борьбы с хроническими заболеваниями требуется постоянный мониторинг деятельности по борьбе с заболеваниями и терапевтическое реагирование в целях оптимизации планов лечения. С учетом растущей доступности методов лечения, позволяющих сглаживать заболевания, крайне важно изучить вопрос о сравнительной эффективности и долгосрочных результатах, помимо тех, которые могут быть получены в ходе выборочных клинических испытаний. Мы внедряем всеобъемлющий трубопровод для получения воспроизводимых и обобщенных реальных данных о результатах болезней за счет использования электронных данных о состоянии

Совпадение в полном тексте источника
… The embedding vectors can be obtained from pre-trained embeddings, such as those powering the ONCE search engine, or by embedding the textual descriptions of the features using large language models such as Clinical BioBERT [ 31 ], CODER [ 32 ], BGE [ 33 ], or even GPT-4 [ 34 ]. … We leveraged the knowledge graph from the ONCE search engine. Given that we were interested in imputing relapse, the query of interest was set to the procedure code for a relevant type of MRI scan (eg, brain MRI). …

Преобразовательный потенциал липидных наночастиц, приспособленных для острой миэлоидной лейкемии.

Технологи, которые занимаются клетками, и инженерная клеточная терапия до сих пор не принесли таких же впечатляющих результатов в острой миэлоидной лейкемии (АМЛ), что и в других гематологическая малигнации. В ходе этого обзора мы анализируем проблемы, связанные с разработкой иммунотерапии для борьбы с отмыванием денег, включая целевую, неопухоль, синдром выброса цитокина (КРС) и «миелиоидный поглотитель». Затем мы обсуждаем появление двух технологий, которые могли бы решить основные проблемы, связанные с проведением расследований по борьбе с отмыванием денег: целенаправленные липидные наночас

A guide to cancer immunotherapy: from T cell basic science to clinical practice.

The T lymphocyte, especially its capacity for antigen-directed cytotoxicity, has become a central focus for engaging the immune system in the fight against cancer. Basic science discoveries elucidating the molecular and cellular biology of the T cell have led to new strategies in this fight, including checkpoint blockade, adoptive cellular therapy and cancer vaccinology. This area of immunological research has been highly active for the past 50 years and is now enjoying unprecedented bench-to-bedside clinical success. Here, we provide a comprehensive historical and biological perspective regar

Navigating the Landscape of Exosomal microRNAs: Charting Their Pivotal Role as Biomarkers in Hematological Malignancies.

Under physiological and pathological conditions, all cells release extracellular vesicles named exosomes, which act as transporters of lipidic, protein, and genetic material from parent to recipient cells. Neoplastic cells can secrete higher number of exosomes to exert pro-tumoral effects such as microenvironmental changes, disease progression, immunosuppression and drug-resistance. This holds true for both organ-specific cancers and hematologic malignancies. One of the most important components of exosomal cargo are microRNAs which can mediate all the abovementioned effects. More specifically

A SITC vision: adapting clinical trials to accelerate drug development in cancer immunotherapy.

Clinical trials of cancer immunotherapy (IO) were historically based on a drug development paradigm built for chemotherapies. The remarkable clinical activity of programmed cell death protein 1/programmed death ligand 1 blockade, chimeric antigen receptor-T cells, and T cell engagers yielded new insights into how the mechanistic underpinnings of IO are reflected in the clinic. These insights and the sheer number of novel immunotherapies currently in the pipeline have made it clear that our strategies and tools for IO drug development must adapt. Recent innovations like engineered T cells and t

Targeting the Endocannabinoidome in Pancreatic Cancer.

Pancreatic Ductal adenocarcinoma (PDAC), the most common malignancy of the pancreas, is an aggressive and lethal form of cancer with a very high mortality rate. High heterogeneity, asymptomatic initial stages and a lack of specific diagnostic markers result in an end-stage diagnosis when the tumour has locally advanced or metastasised. PDAC is resistant to most of the available chemotherapy and radiation therapy treatments, making surgery the most potent curative treatment. The desmoplastic tumour microenvironment contributes to determining PDAC pathophysiology, immune response and therapeutic

Естественные и синтетические АМП из Латинской Америки по всему спектру технологий и приложений в области разнообразия.

Биоразнообразие в Латинской Америке примерно 60% в целом по миру, подпитывая научные исследования в области природных продуктов, весьма значимой области открытия наркотиков по сей день. Это сопровождается увеличением числа антимикробных пептидов (АМП), полученных из натуральных продуктов в регионе, которые за последнее десятилетие были переработаны путем модификации, усовершенствования и уточнения их физико-химических свойств и антимикробной эффективности с использованием подходов, которые варьируются от изучения рациональной конструкции и соотношения структуры-активности (САР) до методов иску

Current challenges and emerging opportunities of chimeric antigen receptor-engineered cell immunotherapy.

Chimeric antigen receptor (CAR) engineered cellular immunotherapy offers the potential for precise targeting and elimination of tumor cells, providing a tailored approach to cancer treatment. CAR-T cells demonstrate significant anti-tumor activity among these therapies. Nonetheless, these therapies may trigger adverse effects, including inflammatory and neurotoxic reactions during treatment. Recent efforts have been directed toward enhancing efficacy by optimizing CAR design or modulating its activity. Compared to CAR-T cells, CAR-engineered natural killer cells (CAR-NK) present notable advant

Unveiling the global research status and intellectual map of cancer and immunosuppressants.

BackgroundThe use of immune checkpoint inhibitors (ICIs) has significantly advanced cancer therapy, improving survival rates and prognosis for many patients. This study employs bibliometric methods to explore the current state and future trends in the field of immunosuppressants and cancer treatment.MethodsData were retrieved from the Science Citation Index Expanded for articles and reviews published between 2014 and 2024 in the Web of Science database. 2,352 records were analyzed using CiteSpace, VOSviewer, R software, and Microsoft Excel. The focus was on publication trends, citations, co-ci

NK cell based immunotherapy against oral squamous cell carcinoma.

Oral squamous cell carcinoma (OSCC), a major subtype of head and neck cancers, presents significant challenges due to its aggressive feature and limited therapeutic efficacy of conventional treatments. In response to these challenges, Natural Killer (NK) cells, a vital component of the innate immune system, are being explored for their therapeutic potential in OSCC due to their inherent ability to target and eliminate cancer cells without prior sensitization. This review uniquely focuses on the evolving role of NK cells specifically in OSCC, incorporating recent advancements in CAR-NK cell eng

Cellular Therapy for Systemic Autoimmune Diseases: New Opportunities for Future Research and Interdisciplinary Collaboration.

Systemic autoimmune diseases (sAIDs) affect 1 in 10 people and represent a leading cause of death in women under the age of 65 years. Despite the emergence of targeted-biologic therapies, mortality rates for sAIDs have not improved. Emerging cellular therapies represent a promising therapeutic strategy for patients living with sAIDs given their potential to induce sustained remission and limit long-term exposure to glucocorticoids. Encouraging outcomes from a case series of patients with systemic lupus erythematosus, idiopathic inflammatory myopathy, and systemic sclerosis (SSc) have ignited c

Эволюция антиCD20 Лечения множественных склерозов: оптимизация характеристик и функций антител.

Истощение клеток B с помощью целевых агентов CD20 обычно используется для лечения множественных склерозов (MS), других аутоиммунных заболеваний и некоторых гематологов. Первоначальный очевидный успех с ритуксимабом в использовании MS и нейромиелитной оптики стимулировал развитие антиCD20 моноклональной антителной (mAb) терапии oprelizumab, atumumab и ublituximab, а также антиCD19 mAb inebilizumab. Хотя каждая из них является эффективной в плане целеопределения и истощения элементов В, структурные различия превращаются в различные механизмы действий, влияющие на поддержание истощения и безопасн

Time to evolve: predicting engineered T cell-associated toxicity with next-generation models.

Despite promising clinical results in a small subset of malignancies, therapies based on engineered chimeric antigen receptor and T-cell receptor T cells are associated with serious adverse events, including cytokine release syndrome and neurotoxicity. These toxicities are sometimes so severe that they significantly hinder the implementation of this therapeutic strategy. For a long time, existing preclinical models failed to predict severe toxicities seen in human clinical trials after engineered T-cell infusion. However, in recent years, there has been a concerted effort to develop models, in

Диагностика и лечение ИГАН: стероиды, Будесонид, или, возможно, и то, и другое?

Нефропатия Ига (IgAN), наиболее часто встречающаяся в мире первичная гломерулонефрит, характеризуется мезангиальным залежем Ига и различными гистологическими повреждениями, как описано в Оксфордской системе классификации. Несмотря на хорошо описываемыеfour-Гипотеза, все еще существует множество менее или неописываемых механизмов, которые участвуют в болезнетворном патогенезе, например B-клеток, который, как представляется, инициируется различными антигенами в кишечном микробиоте. Диагноз болезни в настоящее время основан на результатах биопсии почек, поскольку чувствительность и специфичность

Совпадение в полном тексте источника
… The PubMed search engine was used, and the key words “IgA nephropathy” AND “Steroids” were applied. Moreover, we added two more filters. Only randomized-controlled trials conducted during the last decade were included. … The PubMed search engine was used, and the key words “IgA nephropathy” AND “Budesonide” were applied. We did not take into account case reports. A total of 57 articles were found. After reading the abstracts, we found that five articles had relevant content. …

Oncolytic Viruses as Reliable Adjuvants in CAR-T Cell Therapy for Solid Tumors.

Although impactful scientific advancements have recently been made in cancer therapy, there remains an opportunity for future improvements. Immunotherapy is perhaps one of the most cutting-edge categories of therapies demonstrating potential in the clinical setting. Genetically engineered T cells express chimeric antigen receptors (CARs), which can detect signals expressed by the molecules present on the surface of cancer cells, also called tumor-associated antigens (TAAs). Their effectiveness has been extensively demonstrated in hematological cancers; therefore, these results can establish th

Advances in Adoptive Cell Therapies in Cancer: From Mechanistic Breakthroughs to Clinical Frontiers and Overcoming Barriers.

Adoptive cell therapies (ACTs) have revolutionized cancer treatment by harnessing the specificity and potency of T lymphocytes. Chimeric antigen receptor (CAR)-T cells have achieved landmark successes in B-cell malignancies and multiple myeloma. Tumor-infiltrating lymphocytes (TILs) and T-cell receptor (TCR)-engineered T cells offer complementary strategies to target solid tumors and intracellular antigens. Despite these advances, ACTs face challenges including cytokine release syndrome, neurotoxicity, on-target/off-tumor effects, manufacturing scalability, and immunosuppressive tumor microenv